Stock Market Reviews

AUPH (Aurinia Pharmaceuticals Inc.) News

Get the latest news, insights, and market updates on AUPH (Aurinia Pharmaceuticals Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Aurinia Pharmaceuticals to Report Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provide Update on Recent Business Progress on February 26, 2026
  ROCKVILLE, Md. & EDMONTON, Alberta, February 19, 2026--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced that it will report financial results for the three and twelve months ended December 31, 2025, and provide an update on recent business progress on February 26, 2026.
  Feb 19, 2026 - $AUPH
• Neurocrine Biosciences (NBIX) Lags Q4 Earnings Estimates
  Neurocrine (NBIX) delivered earnings and revenue surprises of -16.55% and +2.89%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
  Feb 11, 2026 - $AUPH
• Investing in Aurinia Pharmaceuticals (NASDAQ:AUPH) a year ago would have delivered you a 80% gain
  If you want to compound wealth in the stock market, you can do so by buying an index fund. But you can significantly...
  Feb 7, 2026 - $AUPH
• This Pharma Stock With Earnings Seen Soaring 1,854% Forms Bullish Base
  This pharma stock projected to post stout earnings growth is forming a bullish chart pattern despite the stock market carnage.
  Feb 6, 2026 - $AUPH
• Moderna Stock Gets Healthy Relative Strength Rating Jump
  A Relative Strength Rating upgrade for Moderna shows improving technical performance. Will it continue?
  Jan 13, 2026 - $AUPH
• With 54% institutional ownership, Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) is a favorite amongst the big guns
  Key Insights Given the large stake in the stock by institutions, Aurinia Pharmaceuticals' stock price might be...
  Jan 11, 2026 - $AUPH
• Is Aurinia Pharmaceuticals (AUPH) Outperforming Other Medical Stocks This Year?
  Here is how Aurinia Pharmaceuticals (AUPH) and Cardinal Health (CAH) have performed compared to their sector so far this year.
  Dec 26, 2025 - $AUPH
• Specific Biologics Welcomes Accomplished Biotechnology Leader Dr. Richard Glickman to its Board of Directors
  Specific Biologics Inc. ("Specific Biologics"), a precision in vivo genome editing company developing highly predictable, efficient and specific Dualase® genome editors to treat the untreatable, today announced the appointment of Dr. Richard Glickman to its Board of Directors.
  Dec 16, 2025 - $AUPH
• Assessing Aurinia Pharmaceuticals After Its 80% 2025 Surge and Lupus Nephritis Momentum
  Wondering if Aurinia Pharmaceuticals is still a smart buy after its big run, or if you have already missed the real upside? This breakdown will help you decide whether the current price matches the underlying value. The stock has climbed 80.7% year to date and 64.6% over the last year, with a 253.0% gain over three years that signals investors have rapidly rewritten their expectations for the business. Much of this momentum has been driven by growing optimism around Aurinia's core lupus...
  Dec 15, 2025 - $AUPH
• Are Medical Stocks Lagging Aurinia Pharmaceuticals (AUPH) This Year?
  Here is how Aurinia Pharmaceuticals (AUPH) and Cardinal Health (CAH) have performed compared to their sector so far this year.
  Dec 10, 2025 - $AUPH